IDEAYA Biosciences (IDYA) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Vericel (VCEL) over the past year, gaining 34.4% versus a gain of 17.3%. Over five years, IDYA leads with a +55.9% price change compared with -21.1% for VCEL. IDEAYA Biosciences is the larger company by market cap ($3.48 billion vs $2.05 billion), about 1.7 times the size.
Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | VCEL |
|---|---|---|
| Share price | $36.06 | $40.05 |
| Market cap | $3.48B | $2.05B |
| 1-day change | -0.55% | -1.69% |
| YTD return | +4.31% | +11.22% |
| 1-year return | +34.35% | +17.35% |
| 5-year return | +55.90% | -21.15% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | — | 47.34 |
| EPS (TTM) | $-1.94 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $276.26M |
| Revenue growth (YoY) | +3024.43% | +16.45% |
| Net income (latest FY) | $-113.70M | $16.52M |
| Gross margin | — | 74.42% |
| Operating margin | -72.84% | 4.00% |
| Net margin | -51.99% | 5.98% |
| 52-week high | $42.68 | $49.32 |
| 52-week low | $26.05 | $28.95 |
| Distance from 52-week high | -15.51% | -18.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +46.28% | +51.24% |
| Average volume | 779.15K | 502.23K |
| Shares outstanding | 96.49M | 51.21M |
| Employees | 145 | 398 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDYA has outperformed VCEL by 17.0 percentage points over the past year.
- Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +16.45%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Healthcare · Biotechnology · 145 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Healthcare · Biotechnology · 398 employees
IDYA vs VCEL FAQ
Which is bigger, IDEAYA Biosciences or Vericel?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.48B compared with $2.05B for Vericel (VCEL).
Which stock has performed better over the past year, IDYA or VCEL?
IDYA returned +34.35% over the past 12 months, compared with +17.35% for VCEL (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Vericel in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.